Follow

Scandion Oncology A/S initiates its second clinical study with SCO-101

28 October 2020 - 12:57

Scandion Oncology A/S is pleased to announce that its second clinical study with SCO-101 has now been initiated. This phase 1B study enrolls metastatic pancreatic cancer patients who will receive SCO-101 together with 1st line standard chemotherapy (Nab-paclitaxel plus gemcitabine) in cohorts of three. The endpoints of this study are safety and efficacy, and the results are expected to be released Q2-Q3, 2021

The Oncology Department at Aalborg University Hospitals will now begin to enroll patients, and Scandion Oncology is engaging additional oncology departments in order to secure a fast and smooth recruitment rate.

For each cohort of patients, the dose of SCO-101 will be increased while the dose of chemotherapy will be held constant. The Maximum Tolerable Dose of SCO-101, when combined with Nab-paclitaxel plus gemcitabine, will be established and once identified additional 3 patients will be included at that dose level. The cancer disease status of each patient is evaluated with CT scan before start of treatment and then every 8 weeks for efficacy measures.

Bo Rode Hansen, CEO, comments: "This second clinical study with SCO-101 is a very important study evaluating SCO-101 in combination with chemotherapy as first line treatment in metastatic pancreatic cancer patients. These patients unfortunately have a very poor outcome as they very quickly develop resistance to chemotherapy. By combining the standard treatment with SCO-101 we expect to significantly improve the survival for these pancreatic cancer patients."

Timelines for clinical studies with SCO-101

  • Colorectal cancer study, first part (dose range finding) expected finalized in Q2, 2021.
  • Pancreatic cancer study, first part (dose range finding) expected finalized in Q2-Q3, 2021
     

For further information regarding Scandion Oncology, please contact:

Bo Rode Hansen, CEO
Phone: +45 28340871
E-mail:
info@scandiononcology.com

This information is information that Scandion Oncology is obliged to publish in accordance to the EU Market Abuse Regulation. The information was provided by the contact person above for publication on October 28, 2020.

 

About Scandion Oncology:

Scandion Oncology A/S is a clinical stage II biotechnology company currently developing first-in-class, oral add-on drugs to existing market leading anti-cancer therapies. As add on to standard anti-cancer therapies, it introduces an effective treatment approach for cancer, which is or has become resistant to cancer-fighting drugs, offering the potential for better response rates, longer survival and improved quality of life. The first-in-class lead candidate, SCO-101, is currently in clinical Phase II. The company is targeting cancer drug resistance in various treatment modalities including, chemotherapy, anti-hormonal therapy and immunotherapy. Scandion Oncology was listed on Spotlight Stock Market, Sweden in November 2018. Ticker code: SCOL

Provided by: Cision
Spotlight (Sweden)
Scandion Oncology A/S
Scandion is a biotechnology company. The company develops pharmaceuticals for the treatment of cancer containing drug-resistant cell clones. The leading product of the company, SCO-101, has shown to improve the effect of certain standard cancer treatments during preclinical studies. The head office of the company is located in Copenhagen....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More

Create Your FREE Account to stay Up To Date